Document is current
Any future updates will be listed below
-
Authors
Hamdi, Wafa https://orcid.org/0000-0003-3045-4831
Migowa, Angela https://orcid.org/0000-0002-1146-7963
Ferjani, Hanene Lassoued https://orcid.org/0000-0002-8658-0936
Makhloufi, Chafia Dahou https://orcid.org/0000-0002-6523-9851
Makhlouf, Yasmine https://orcid.org/0000-0001-8788-0626
Nasef, Samah Ismail https://orcid.org/0000-0002-8875-2455
Ziade, Nelly https://orcid.org/0000-0002-4479-7678
Baraliakos, Xenophone https://orcid.org/0000-0002-9475-9362
Brunner, Hermine https://orcid.org/0000-0001-9478-2987
Hassan, Mohammed https://orcid.org/0000-0001-8436-8598
Libe, Temesgen https://orcid.org/0000-0003-4452-5573
Palalane, Elisa
Hassan, Waleed https://orcid.org/0000-0002-3238-6804
Sobh, Ali https://orcid.org/0000-0001-7047-076X
Seri, Ahmed https://orcid.org/0009-0000-2690-6538
Mosad, Doaa https://orcid.org/0000-0002-1220-7215
Lishan, Hanna https://orcid.org/0000-0002-4668-2575
Taha, Yassmin https://orcid.org/0009-0005-0623-2878
Gacem, Ourida https://orcid.org/0000-0002-9690-0569
Hashed, Soad https://orcid.org/0000-0003-0500-7458
Furia, Francis Fredrick https://orcid.org/0000-0003-2668-3041
Slimani, Samy https://orcid.org/0000-0001-9332-3551
Scott, Christiaan https://orcid.org/0000-0003-3874-1704
Hadef, Djohra
- License Information
-
More Information
Article History
Received: 12 December 2024
Revised: 7 January 2025
Accepted: 11 January 2025
First Online: 1 February 2025
Compliance with ethical standards
:
: Xenophone Baraliakos’ COI are Research Grants, Consultant, Scientific Advisory Board: Abbvie, Alphasigma, Amgen, BMS, Cesas, Celltrion, Galapagos, Janssen, Lilly, Moonlake, Novartis, Pfizer, Roche, Sandoz, Springer, Stada, Takeda, UCB, Zuellig. Non-commercial disclosures: ASAS President, EULAR President-Elect, VRA Board Member.Other authors declare no conflict of interest related to the manuscript or the preparation of the guidelines.
